2014


To access this material please log in or register

Register Authorize
2014/№4

Clinical studies on patients with circulatory decompensation. Possible ways of optimization

Arutyunov A. G.
State Budgetary Educational Institution of Higher Professional Education, “N.I. Pirogov Russian National Research Medical University” of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: circulatory decompensation, prognosis, patient phenotype, CHF


DOI: 10.18087/rhfj.2014.4.1970

The issue of decompensated CHF has been one of the most burning in current cardiology. In European countries, decompensated CHF causes 5 % of all urgent hospitalizations and is observed in 10 % of all admitted patients. Generally, patients with CHF are elderly people with many comorbidities, which makes prognosis of such patients unfavorable. Introduction of the notion of HF patient phenotype will allow physicians to choose a strategy and tactics for the treatment and to have an idea of the prognosis already during early management of the patient.
  1. Ezekowitz JA, Kaul P, Bakal JA. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. JACC 2009 Jan 6;53 (1):13–20.
  2. Felker GM, Leimberger JD, Callif RM et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004 Dec;10 (6):460–466.
  3. Lee DS, Austin PC, Rouleau JL et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. J Am Med Assoc. 2003 Nov 19;290 (19):2581–2587.
  4. McMurray JJ, Teerlink JR, Cotter G et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007 Nov 7;298 (17):2009–2019.
  5. Packer M, Colucci W, Fisher L et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Failure. 2013 Apr;1 (2):103–111.
  6. Califf RM. Better late than never: a welcome publication of tardy clinical trial results. JACC Heart Failure. 2013 Apr;1 (2):112–114.
  7. Konstam MA, Gheorghiade M, Burnett JC et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA. 2007 Mar 28;297 (12):1319–1331.
  8. Gheorghiade M, Konstam MA, Burnett JC et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials. JAMA. 2007 Mar 28;297 (12):1332–1343.
  9. Yancy CW. Climbing the mountain of acute decompensated heart failure: the EVEREST trials. JAMA. 2007 Mar 28;297 (12):1374–1376.
  10. Massie BM, O'Connor CM, Metra M et al. Rolofylline, an adeno­sine A1−receptor antagonist, in acute heart failure. N Engl J Med. 2010 Oct 7;363 (15):1419–1428.
  11. Teerlink JR, Cotter G, Davidson BA et al. Serelaxin, recombinant human relaxin – 2, for treatment acute heart failure (RELAX-AHF): a randomized, placebo – controlled trial. Lancet. 2013 Jan;381 (9860):29–39.
Arutyunov A. G. Clinical studies on patients with circulatory decompensation. Possible ways of optimization. Russian Heart Failure Journal. 2014;85 (4):250–253

To access this material please log in or register

Register Authorize
Ru En